Interview: Eoin Vaughan – CEO; Dermot Gildea – Director of Life Sciences, Mercury Engineering, Ireland

Eoin Vaughan, CEO of Mercury Engineering, and Dermot Gildea, Director of Life Sciences, highlight the key priorities of their exciting new Mercury 2021 strategy, the rationale behind their transition into a sector-based company rather than a geography-based one, their commitment to continuous improvement in terms of staff capabilities and technology, and their ambition to position Mercury Engineering as the best multidisciplinary engineering contractor in the healthcare and life sciences sectors in Europe. Eoin, you were appointed CEO of Mercury Engineering in 2014. What have been some highlights for Mercury in the past two years?
"We are intimately familiar with the culture of safety, the quality, the specific demands and the timelines that FDI clients need. This is particularly relevant to the life sciences industry given that it is so tightly regulated."
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report